Skip to news
JQJO
Latest

Alzheimer's Drug Delays Onset in Genetic Study | JQJO

Alzheimer's Drug Delays Onset in Genetic Study

Alzheimer's Drug Delays Onset in Genetic Study

Tap title to read story

0:00 / 0:38

A small study involving individuals with genetic mutations predisposing them to Alzheimer's shows that the biologic drug gantenerumab may significantly delay the onset of symptoms when administered early and consistently for extended periods (up to eight years). The 22 participants who received the drug longest experienced a nearly 50% reduction in symptom risk. While promising, outside experts caution about the study's small size and lack of a placebo control group. Funding for the ongoing research is threatened, raising concerns about continued access to the drug and hindering further investigation.

Published · Published by JQJO

Published by JQJO Editorial Desk · AI assisted

JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.

Editorial policy and corrections · Our team

JQJO

Find your next story

Search JQJO’s current coverage.